Acute Versus Subacute Angioplasty in Patients With NON-ST-Elevation Myocardial Infarction

Myocardial Infarction Clinical Trial

— NONSTEMI  

Official title:

Acute Versus Subacute Angioplasty in Patients With NON-ST-Elevation Myocardial Infarction (NON-ST-Elevation Myocardial Infarction=NONSTEMI Trial)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01638806
• Other study ID #: NONSTEMI
• Status: Terminated
• Phase: N/A
• Start date: June 2012
• Est. completion date: April 2017

Study information

• Verified date: April 2019
• Source: Aarhus University Hospital Skejby
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with acute myocardial infarction (AMI) are categorized according to the electrocardiogram (ECG) findings into: 1) patients with ST-Elevation Myocardial Infarction (STEMI), 2) patients with Bundle Branch Block Myocardial Infarction (BBBMI), and 3) remaining patients with so-called NON-ST-Elevation Myocardial Infarction (NONSTEMI).

Patients with STEMI or BBBMI are treated with acute angioplasty (PPCI=primary percutaneous coronary intervention), and the sooner PPCI is performed the lower is the mortality. This is why prehospital diagnosis and field-triage of patients with STEMI directly to heart centers with PPCI facilities is recommended.

In patients with NONSTEMI previous trials have indicated that early angioplasty, within 72 hours of symptom onset, is associated with improved outcome when compared to late angioplasty or conservative therapy. No trials have so far been able to diagnose patients with NONSTEMI in the prehospital phase or immediately on arrival at a hospital, and triage them directly to PPCI. Implementation of point-of-care (POC) testing of biomarkers may enable prehospital or early inhospital establishment of the diagnosis NONSTEMI.

The aim of the present trial is to identify patients with NONSTEMI in the prehospital phase or immediately on arrival at the local hospital based on a) symptoms, b) POC testing and c) ECG findings and then randomize patients to I) PPCI, or II) medical therapy and angiography/angioplasty within 72 hours (todays routine).

Se below for detailed description

Description:

In the present trial patients with a) typical angina pectoris (AP) combined with b1) rise in biomarkers on POC testing (prehospital/immediately inhospital) and/or b2) ST-segment depression of more than 0.2 mV in two contiguous leads or more than 0.1 mV in four contiguous leads are randomized to I) PPCI (same protocol as in STEMI patients) or II) medical therapy and angiography/angioplasty within 72 hours (todays routine practice).

The primary purposes of the present trial is threefold:

1. To evaluate if it is possible to diagnose patients with NONSTEMI in the prehospital phase or immediately on arrival at the hospital (N=250 patients)

2. To compare a combined endpoint of mortality, re-infarction (during index admission or readmitted), or readmission with Congestive Heart Failure (CHF) between group I (PPCI strategy) and group II (routine strategy) (N=2500 patients).

3. To compare mortality between group I and II (N=4500 patients).

Secondary purposes of the present trial is:

1. To evaluate whether there is difference in the primary endpoints in patients randomized within or after 12 hours of symptom onset.

2. To evaluate whether there is difference in the primary endpoints in patients randomized in the prehospital phase and on admission to the hospital, respectively.

3. To evaluate whether there is difference in the primary endpoints in patients with a final diagnosis of AMI, as adjudicated by a clinical event committee.

4. To evaluate whether there is difference in the primary endpoints in patients with or without diabetes, respectively.

5. To compare a combined endpoint of mortality, readmission with AMI, readmission with CHF, readmission with AP, revascularization (not planned on index admission).

6. To compare a combined safety endpoint of stroke or serious bleeding between group I and II.

7. To evaluate if there is difference in the frequency of PCI and CABG in group I versus II.

8. To compare total admission time between group I and II.

9. To compare total cost between group I and II.

10. To compare total duration where the patient is on sick leave between group I and II

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 500
• Est. completion date: April 2017
• Est. primary completion date: April 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Angina

• Elevated biomarkers (Point-of-care testing) either prehospital or immediately on admission

• ST-segment depression of 0.2mV or more in two contiguous leads or 0.1 mV or more in four contiguous leads.

• Patient can be randomized either in the prehospital phase or within 30 minutes of admission to a hospital

Exclusion Criteria:

• Tachycardia > 120

• Age < 18 or > 80 years

• Indication for PPCI already fulfilled

• Dementia

• Patient cannot understand the study information

• Presumed "troponisme"

• Left ventricular hypertrophy

• Known dialysis

• Previous CABG

• Pregnancy

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction
• Non-ST Elevated Myocardial Infarction

Intervention

Procedure:
• Group I: Primary PCI
Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI

Locations

Country	Name	City	State
Denmark	Department of cardiology, Aarhus University Hospital in Skejby	Aarhus

Sponsors (1)

Lead Sponsor	Collaborator
Aarhus University Hospital Skejby

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality	all-cause mortality	within 1 year from randomization
Primary	Re-infarction	Re-infarction (during index admission or readmitted) adjudicated by and endpoint committee. The endpoint committee is blinded to the initial randomization. The "Universal definition of Myocadial infarction" will be used to classify reinfarction. Biomarkers will be recorded with emphasis on the need of obtaining blood samples until a peak has been reached during index hospitaltization before reinfarction can be considered. Re-infarction will require a 20% relative rise in biomarker level.	within 1 year from randomization
Primary	Readmission with CHF	Readmission or visit in the outpatient clinic with CHF. Readmission or visit with CHF needs to be adjudicated by an endpoint committee blinded to the initial randomization.	within 1 year from randomization
Primary	Confirmed AMI	An endpoint committee needs to evaluate whether each patient had AMI on the index admission. This evaluation is performed without the endpoint committee being aware whether the patient was randomized to PPCI or conventional therapy. The endpoint committee will classify whether the patient had: a) NONSTEMI, b) STEMI with symptom duration <=12 hours, c) STEMI with symptom duration >12 hours, d) BBBMI with symptom duration <=12 hours or e) BBBMI with symptom duration > 12 hours.	during index admission
Secondary	Readmission with AP	The national health registry is used to determine whether the patient is readmitted with AP. Time from index admission to first readmission with AP is determined. The endpoint committee adjudicate readmissions with AP blinded to original treatment strategy (Group I versus II)	within 3 months, 1 year, and 5 year from randomization
Secondary	Readmission with stroke	The national health registry used to determine whether the patient is readmitted with stroke. Stroke was defined as focal loss of neurologic function caused by an ischemic or hemorrhagic event, with residual symptoms lasting at least 24 hours or leading to death. Time from index admission to first readmission with stroke is determined. The endpoint committee adjudicate readmissions with stroke blinded to original treatment strategy (Group I versus II).	within 3 months, 1 year, and 5 year from randomization
Secondary	Non-scheduled re-intervention	The national health registry is used to determine whether the patient has non-scheduled re-intervention performed (re-intervention not scheduled at index admission). Time from index admission to first re-intervention and type of re-interverntion (PCI or CABG) is determined. The endpoint committee adjudicate re-interventions blinded to original treatment strategy (Group I versus II)	within 3 months, 1 year, and 5 year from randomization
Secondary	Duration of index admission	The national health registry is used to determine number of days the patietns was admitted during index hospitalization (local hospital and interventional hospital).	Time from initial admission to discharge
Secondary	Sick-leave from work	The national DREAM database is used to determined whether the patient is on sick leave from work after index hospitalization and the duration of sick leave from work.	within 3 months, 1 year, and 5 year from randomization
Secondary	Total cost	The total cost for each treatment strategy is calculated: EMS-transport, admission, cost for PCI / CABG.	within 3 months, 1 year, and 5 year from randomization
Secondary	Bleeding	The national health registry is used to determine bleeding events. The same criteria for bleeding classification is used as in the PLATO trial (see NEJM 2009 for details) to categorize: 1) Major life-threatening bleeding, 2) Other major bleeding. In addition BARC type 4 (CABG-related) bleedings are registered.	within 3 months, 1 year, and 5 year from randomization
Secondary	Time to intervention	The time frame is equal to the health care system delay (time from EMS call to intervention)	Time from ambulance call to PCI or CABG is performed or angiography is performed without indication for PCI or CABG
Secondary	Cardiovascular mortality	Cardiovascular mortality according to the Danish Registry of Cause of Death.	within 3 months, 1 year, and 5 year from randomization